Literature DB >> 7907893

Assessment of the wheal size and skin blood flow of the erythema induced by histamine and its modification with cetirizine and ebastine: a crossover, double-blind study.

J de la Cuadra1, M Teruel, P Teixidó, J Roma.   

Abstract

In order to assess the antihistaminic power of cetirizine and ebastine, we designed a randomized, double-blind, crossover study, measuring their capacity to modify skin blood flow induced by a histamine prick test. The vasomotor response was compared using a laser Doppler flowmeter. Two hours after intake of the antihistaminic drug, there were significant differences between both drugs: at 4 h, the antihistaminic effect of cetirizine persists, whereas ebastine only showed moderate activity. The reduction of the cutaneous blood flow values (CBFV) showed good activity in both groups, but cetirizine was more potent and showed faster activity than ebastine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907893     DOI: 10.1159/000247117

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  5 in total

Review 1.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Ebastine: an update of its use in allergic disorders.

Authors:  M Hurst; C M Spencer
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 3.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Histamine response and local cooling in the human skin: involvement of H1- and H2-receptors.

Authors:  M Grossmann; M J Jamieson; W Kirch
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

Review 5.  Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.